We are currently experiencing technical issues due to the Microsoft outage. This will affect delivery of multi-factor authentication emails, invoice emails and service emails. We apologise for the disruption.

Explore 3 Stock Ideas & Industry Insights Download Free Report

18889881171
Shopping Cart 0
countryflagUS
Login

Home CompaniesMinerva Neurosciences Inc

Minerva Neurosciences Inc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
2.42 USD -0.14 ( 5.47%)
Last update at 2026-11-12T15:45:00Z
VOLUME
6359
Market Cap
182.87M

Momentum Score

…

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone, which is in Phase 3 confirmatory trial for the treatment of negative symptoms in patients with schizophrenia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
2.38
Low
2.53
High
52 Week Price Range
1.93
Low
8.80
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Minerva Neurosciences is a clinical-stage biopharmaceutical company developing treatments for central nervous system disorders, notably neuropsychiatric conditions such as schizophrenia. Long-term growth may be driven by clinical progress, regulatory approvals and partnerships to commercialize pipeline assets addressing negative symptoms and cognitive impairment, which could attract investors seeking specialty CNS exposure.

Main risks include high clinical and regulatory uncertainty for CNS therapies and limited cash runway that may require dilutive financing or strategic partnerships.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
2.56
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
-15.54M
Debt / Equity
-0.46
ROE
-675.09%
Net Debt
-17.34M
ROCE
-306.67%
Diluted EPS TTM
-34.41

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -293.42M 1.44M -30.01M -32.11M -51.71M
Net income -293.42M 1.44M -30.01M -38.99M -49.91M
Selling general administrative 9.34M 9.95M 10.41M 10.58M 13.33M
Selling and marketing expenses - 9939.84M 10403.94M - -
Gross profit -0.01M -0.02M -0.03M - -
Reconciled depreciation 0.01M 0.02M 0.03M 0.01M 0.10M
Ebit -293.42M 6.00M -21.72M -25.23M -45.37M
Ebitda -293.42M 6.02M -21.69M -25.22M -45.26M
Depreciation and amortization 0.01M 0.02M 0.03M 0.01M 0.10M
Operating income -15.10M -21.85M -23.12M -25.23M -45.37M
Other operating expenses 15.10M 21.85M 23.12M 25.23M 45.37M
Interest expense 0.00M 4.56M 8.28M 7.41M 6.33M
Tax provision - - - 0.00M -1.80M
Interest income - - 1.44M - -
Net interest income -3.10M -4.56M -8.02M -7.41M -6.33M
Income tax expense - - -0.00M 6.88M -1.80M
Total revenue 0.00M 0.00M 0.00M 0.00M 0.00M
Total operating expenses 15.10M 21.85M 23.12M 25.23M 45.37M
Cost of revenue 0.01M 0.02M 0.03M - -
Total other income expense net -278.32M 23.29M -6.89M -6.88M -6.34M
Net income from continuing ops -293.42M 1.44M -27.71M -32.11M -49.91M
Net income applicable to common shares - - - -32.11M -49.91M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 97.97M 37.14M 56.90M 55.09M 77.12M
Intangible assets - 14854.53M 0.02M 0.04M 0.05M
Other current assets 0.80M 0.91M 0.99M 3.97M 1446.36M
Total liab 238.72M 62.84M 85.36M 75.11M 69.15M
Total stockholder equity -140.75M -25.69M -28.46M -20.02M 7.98M
Other current liab 1.65M 1.23M 1.54M 0.41M 0.97M
Common stock 0.00M 0.00M 0.00M 0.00M 0.00M
Capital stock 0.00M 0.00M 0.00M 0.00M 0.00M
Retained earnings -688.80M -395.38M -396.82M -366.81M -334.70M
Other liab - - - 73.73M 66.33M
Good will 14.87M 14.87M 14.87M 14.87M 14.87M
Other assets - 0.00M - - 1.50M
Cash 82.30M 21.36M 41.01M 36.09M 60.76M
Total current liabilities 2.29M 2.84M 3.34M 1.38M 2.82M
Net debt -17.34M -21.36M 41.00M -36.09M -60.76M
Short long term debt total 64.96M 60.00M 82.02M - -
Other stockholder equity 548.05M 369.68M 368.36M 346.79M 342.67M
Property plant equipment - - - 0.02M -
Total current assets 83.10M 22.27M 42.00M 40.16M 62.20M
Net tangible assets - - - -34.94M -6.94M
Short term investments - 0.10M - - -
Net receivables - - - 3.12M -
Accounts payable 0.64M 1.61M 1.81M 0.97M 1.85M
Non currrent assets other - -21340.54M 27.91M 0.06M -
Non current assets total 14.87M 14.87M 14.90M 14.93M 14.92M
Capital lease obligations - - - - 0.00M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - 0.00M -0.02M -0.02M 0.00M
Change to liabilities - - - -0.88M 0.86M
Total cashflows from investing activities - - - -0.02M -0.02M
Total cash from financing activities 74450.74M 0.00M 19.60M -0.00M 60.00M
Change to operating activities - - - -3.18M -0.60M
Net income -293.42M 1.44M -30.01M -32.11M -49.91M
Change in cash 60939.81M -19.55M 4.82M -24.66M 35.40M
Begin period cash flow 21462.01M 41.01M 36.19M 60.86M 25.46M
End period cash flow 82401.81M 21.46M 41.01M 36.19M 60.86M
Total cash from operating activities -13510.94M -19.55M -14.78M -24.65M -24.60M
Issuance of capital stock 80.00M 0.00M 20.00M - 0.00M
Depreciation 5.44M 0.02M 0.03M 0.01M 0.10M
Other cashflows from financing activities 74376.29M - -0.40M -0.00M 60.00M
Change to netincome - - - 11.52M 24.94M
Capital expenditures 0.00M 0.00M 0.00M 0.02M 0.02M
Change in working capital -0.63M -0.32M 4.94M -4.06M 0.26M
Stock based compensation 1327.37M 1.33M 1.97M 4.11M 5.22M
Other non cash items -14549.69M -22.02M 8.28M 1810.76M 21.53M
Free cash flow -13510.94M -19.55M -14.78M -24.66M -24.60M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
NERV
Minerva Neurosciences Inc		 -0.14
5.47%		 2.42 - 11.21 1.87 2.68 0.03 2.60
NVO
Novo Nordisk A/S		 -0.54
1.32%		 40.55 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -2.37
0.43%		 544.66 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc		 -2.77
0.29%		 956.64 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Minerva Neurosciences Inc

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone, which is in Phase 3 confirmatory trial for the treatment of negative symptoms in patients with schizophrenia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.

1500 District Avenue, Burlington, MA, United States, 01803

617 600 7373

https://www.minervaneurosciences.com

7

Name Title Year Born
Dr. Remy Luthringer Ph.D. Exec. Chairman & CEO 1961
Mr. Geoffrey Robin Race F.C.M.A., FCMA, M.B.A., MBA Pres 1961
Mr. Frederick W. Ahlholm CPA, CPA Sr. VP, CFO & Sec. 1966
Prof. Michael Davidson M.D. Chief Medical Officer 1950
Mr. Joseph Reilly Sr. VP & COO 1975
Mr. William B. Boni VP of Investor Relations & Corp. Communications 1952
Dr. Ramana Kuchibhatla Ph.D. Sr. VP and Head of R&D NA
Dr. Remy Luthringer Ph.D. Executive Chairman & CEO 1961
Mr. Geoffrey Robin Race F.C.M.A., M.B.A. President 1961
Mr. Frederick W. Ahlholm CPA Senior VP, CFO & Secretary 1966

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

No data available
No data available

Equity Sectors*

  • Basic Materials

    -1.40%

  • Communication Services

    -0.45%

  • Consumer Cyclical

    -0.55%

  • Consumer Defensive

    -0.01%

  • Energy

    -0.01%

  • Financial Services

    -0.40%

  • Financials

    -0.15%

  • Healthcare

    -1.15%

  • Industrials

    -0.46%

  • Real Estate

    -0.29%

  • Technology

    -1.22%

  • Utilities

    -0.10%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…